Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of mepolizumab in refractory or relapsing Churg-Strauss syndrome
2006-001791-20Phase 2Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Attaining remission. Started Jan 2008; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2006-001791-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001791-20.